Membranous nephropathy in the kidney allograft

Area of Science:

• Nephrology
• Transplantation Immunology

Background:

• Membranous nephropathy (MN) in kidney transplants presents as either disease recurrence (rMN) or de novo onset (dnMN).
• rMN typically manifests early post-transplant, often subclinically, and is characterized by progressive proteinuria with limited spontaneous remission potential.
• dnMN occurs with similar frequency to rMN and shares characteristics with secondary MN in native kidneys.

Purpose of the Study:

• To differentiate the clinical behavior and management considerations for recurrent (rMN) versus de novo (dnMN) membranous nephropathy in kidney transplant recipients.
• To review the diagnostic criteria and potential therapeutic strategies for both rMN and dnMN.
• To highlight the importance of monitoring antiphospholipase A2 receptor (PLA2R) antibodies in managing MN post-transplantation.

Main Methods:

• Review of existing literature on kidney transplant recipients diagnosed with membranous nephropathy.
• Analysis of clinical features, natural history, and treatment outcomes for rMN and dnMN.
• Evaluation of the role of antiphospholipase A2 receptor (PLA2R) antibody testing in diagnosis and management.

Main Results:

• Recurrent MN (rMN) often occurs within the first year, shows progressive proteinuria, and has a lower chance of spontaneous remission compared to primary MN (pMN).
• Antiphospholipase A2 receptor (PLA2R) antibody evaluation is crucial; persistent or rising titers warrant biopsy, as does proteinuria exceeding 1 g/day.
• De novo MN (dnMN) is associated with factors like viral infections and potential atypical alloimmune responses; its treatment, including rituximab, is less defined than for rMN.

Conclusions:

• Given the progressive nature of rMN and lack of spontaneous remission, prompt management is indicated, with observational data supporting rituximab use.
• dnMN requires investigation into underlying causes such as viral infections or alloimmune responses, with treatment tailored accordingly.
• Monitoring PLA2R antibody status and proteinuria levels are key components in managing both recurrent and de novo membranous nephropathy after kidney transplantation.